Technical Analysis for SPRB - Spruce Biosciences, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 0.70 | -0.14% | 0.00 |
SPRB closed down 0.14 percent on Friday, April 26, 2024, on 14 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.
Earnings due: May 13
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Very Strong | Down | Down | Flat |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| NR7 | Range Contraction | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| Inside Day | Range Contraction | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Narrow Range Bar | Range Contraction | -0.14% | |
| Oversold Stochastic | Weakness | -0.14% | |
| Narrow Range Bar | Range Contraction | -0.26% | |
| Oversold Stochastic | Weakness | -0.26% | |
| Shooting Star Candlestick | Bearish | -0.17% | |
| Narrow Range Bar | Range Contraction | -0.17% |
| Alert | Time |
|---|---|
| Possible NR7 | about 12 hours ago |
| Possible Inside Day | about 12 hours ago |
| 60 Minute Opening Range Breakdown | about 13 hours ago |
| 10 DMA Resistance | about 13 hours ago |
| 10 DMA Support | about 17 hours ago |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/13/2024
Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company develops tildacerfont, an non-steroidal therapy, which is in Phase IIb clinical trial for adult patients with classic congenital adrenal hyperplasia (CAH) and in Phase II clinical trial in children with classic CAH. It is also developing tildacerfont for females with polycystic ovary syndrome. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses. Spruce Biosciences, Inc. was founded in 2014 and is headquartered in Daly City, California.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Hyperplasia Endocrine Disorders Congenital Adrenal Hyperplasia Neurocrine Biosciences
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Hyperplasia Endocrine Disorders Congenital Adrenal Hyperplasia Neurocrine Biosciences
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 5.95 |
| 52 Week Low | 0.6711 |
| Average Volume | 1,528,570 |
| 200-Day Moving Average | 2.23 |
| 50-Day Moving Average | 2.44 |
| 20-Day Moving Average | 0.75 |
| 10-Day Moving Average | 0.70 |
| Average True Range | 0.12 |
| RSI (14) | 24.24 |
| ADX | 51.68 |
| +DI | 13.36 |
| -DI | 41.33 |
| Chandelier Exit (Long, 3 ATRs) | 0.51 |
| Chandelier Exit (Short, 3 ATRs) | 1.03 |
| Upper Bollinger Bands | 0.86 |
| Lower Bollinger Band | 0.64 |
| Percent B (%b) | 0.28 |
| BandWidth | 29.89 |
| MACD Line | -0.37 |
| MACD Signal Line | -0.48 |
| MACD Histogram | 0.1139 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 0.72 | ||||
| Resistance 3 (R3) | 0.72 | 0.72 | 0.72 | ||
| Resistance 2 (R2) | 0.72 | 0.71 | 0.71 | 0.71 | |
| Resistance 1 (R1) | 0.71 | 0.71 | 0.71 | 0.71 | 0.71 |
| Pivot Point | 0.70 | 0.70 | 0.70 | 0.70 | 0.70 |
| Support 1 (S1) | 0.70 | 0.70 | 0.69 | 0.69 | 0.69 |
| Support 2 (S2) | 0.69 | 0.69 | 0.69 | 0.69 | |
| Support 3 (S3) | 0.68 | 0.69 | 0.68 | ||
| Support 4 (S4) | 0.68 |
